{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:49:46Z","timestamp":1792014586583,"version":"4.4.0"},"reference-count":148,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"DOI":"10.1007\/s12325-026-03814-x","type":"journal-article","created":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:12:46Z","timestamp":1792012366000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ibogaine for Substance Use Disorders"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3140-357X","authenticated-orcid":false,"given":"Ahmed I.","family":"Anwar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul-rahman A.","family":"Hegazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Farris","family":"Sawaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua R.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey E.","family":"Lashley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jillian M.","family":"Gatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristy M.","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibraheem A.","family":"Hachem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly E.","family":"McNulty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Destiny S.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin S.","family":"Murnane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan D.","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,14]]},"reference":[{"issue":"1","key":"3814_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-025-22814-0","volume":"25","author":"J An","year":"2025","unstructured":"An J, Wang Q, Bai Z, Du X, Yu D, Mo X. Global burden and trend of substance use disorders, self-harm, and interpersonal violence from 1990 to 2021, with projection to 2040. BMC Public Health. 2025;25(1):1632. https:\/\/doi.org\/10.1186\/s12889-025-22814-0.","journal-title":"BMC Public Health"},{"key":"3814_CR2","unstructured":"Substance Abuse and Mental Health Services Administration. (2023). Key substance use and mental health indicators in the United States: Results from the 2022 National Survey on Drug Use and Health (HHS Publication No.PEP23-07-01-006, NSDUH Series H-58). Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. https:\/\/www.samhsa.gov\/data\/report\/2022-nsduh-annual-national-report."},{"issue":"7","key":"3814_CR3","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.22303","volume":"6","author":"T Gomes","year":"2023","unstructured":"Gomes T, Ledlie S, Tadrous M, Mamdani M, Paterson JM, Juurlink DN. Trends in opioid toxicity-related deaths in the US before and after the start of the COVID-19 pandemic, 2011-2021. JAMA Netw Open. 2023;6(7):e2322303. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.22303.","journal-title":"JAMA Netw Open"},{"issue":"2","key":"3814_CR4","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1176\/appi.ajp.2018.17070732","volume":"176","author":"MA Sullivan","year":"2019","unstructured":"Sullivan MA, Bisaga A, Pavlicova M, et al. A randomized trial comparing extended-release injectable suspension and oral naltrexone, both combined with behavioral therapy, for the treatment of opioid use disorder. Am J Psychiatry. 2019;176(2):129\u201337. https:\/\/doi.org\/10.1176\/appi.ajp.2018.17070732.","journal-title":"Am J Psychiatry"},{"key":"3814_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2024.173952","volume":"248","author":"JS Raymond","year":"2025","unstructured":"Raymond JS, Athanasopoulos AG, Badolato CJ, et al. Emerging medications and pharmacological treatment approaches for substance use disorders. Pharmacol Biochem Behav. 2025;248:173952. https:\/\/doi.org\/10.1016\/j.pbb.2024.173952.","journal-title":"Pharmacol Biochem Behav"},{"issue":"3","key":"3814_CR6","doi-asserted-by":"publisher","first-page":"386","DOI":"10.3390\/jox13030025","volume":"13","author":"RB Kargbo","year":"2023","unstructured":"Kargbo RB. Microbiome: the next frontier in psychedelic renaissance. J Xenobiot. 2023;13(3):386\u2013401. https:\/\/doi.org\/10.3390\/jox13030025.","journal-title":"J Xenobiot"},{"issue":"3","key":"3814_CR7","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1080\/105504999305848","volume":"8","author":"KR Alper","year":"1999","unstructured":"Alper KR, Lotsof HS, Frenken GM, Luciano DJ, Bastiaans J. Treatment of acute opioid withdrawal with ibogaine. Am J Addict. 1999;8(3):234\u201342. https:\/\/doi.org\/10.1080\/105504999305848.","journal-title":"Am J Addict"},{"issue":"3","key":"3814_CR8","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1523\/JNEUROSCI.3959-04.2005","volume":"25","author":"DY He","year":"2005","unstructured":"He DY, McGough NNH, Ravindranathan A, et al. Glial cell line-derived neurotrophic factor mediates the desirable actions of the anti-addiction drug ibogaine against alcohol consumption. J Neurosci. 2005;25(3):619\u201328. https:\/\/doi.org\/10.1523\/JNEUROSCI.3959-04.2005.","journal-title":"J Neurosci"},{"issue":"4","key":"3814_CR9","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1111\/j.1476-5381.1996.tb15253.x","volume":"117","author":"MEM Benwell","year":"1996","unstructured":"Benwell MEM, Holtom PE, Moran RJ, Balfour DJK. Neurochemical and behavioural interactions between ibogaine and nicotine in the rat. Br J Pharmacol. 1996;117(4):743\u20139. https:\/\/doi.org\/10.1111\/j.1476-5381.1996.tb15253.x.","journal-title":"Br J Pharmacol"},{"issue":"3","key":"3814_CR10","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/0091-3057(94)90092-2","volume":"49","author":"PA Broderick","year":"1994","unstructured":"Broderick PA, Phelan FT, Eng F, Wechsler RT. Ibogaine modulates cocaine responses which are altered due to environmental habituation: in vivo microvoltammetric and behavioral studies. Pharmacol Biochem Behav. 1994;49(3):711\u201328. https:\/\/doi.org\/10.1016\/0091-3057(94)90092-2.","journal-title":"Pharmacol Biochem Behav"},{"issue":"1","key":"3814_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51856-y","volume":"15","author":"V Havel","year":"2024","unstructured":"Havel V, Kruegel AC, Bechand B, et al. Oxa-iboga alkaloids lack cardiac risk and disrupt opioid use in animal models. Nat Commun. 2024;15(1):8118. https:\/\/doi.org\/10.1038\/s41467-024-51856-y.","journal-title":"Nat Commun"},{"issue":"3","key":"3814_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/molecules31030545","volume":"31","author":"MP Esperan\u00e7a","year":"2026","unstructured":"Esperan\u00e7a MP, Gomes NGM, Campos MG. Ibogaine: therapeutic potential, cardiac safety, and translational perspectives in the treatment of substance use disorders\u2014a scoping review. Molecules. 2026;31(3):545. https:\/\/doi.org\/10.3390\/molecules31030545.","journal-title":"Molecules"},{"issue":"844","key":"3814_CR13","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1111\/j.1749-6632.1998.tb08237.x","volume":"30","author":"SD Glick","year":"1998","unstructured":"Glick SD, Maisonneuve IS. Mechanisms of antiaddictive actions of ibogaine. Ann N Y Acad Sci. 1998;30(844):214\u201326.","journal-title":"Ann N Y Acad Sci"},{"key":"3814_CR14","doi-asserted-by":"publisher","DOI":"10.1177\/20503245251380511","volume":"11","author":"DJ Nutt","year":"2025","unstructured":"Nutt DJ, Erritzoe D, Schlag A, et al. A lexicon for psychedelic research and treatment. Drug Sci Policy Law. 2025;11:20503245251380511. https:\/\/doi.org\/10.1177\/20503245251380511.","journal-title":"Drug Sci Policy Law"},{"key":"3814_CR15","doi-asserted-by":"publisher","DOI":"10.1017\/neu.2026.10059","volume":"38","author":"T Calvey","year":"2026","unstructured":"Calvey T, Govender D, Owen GR, et al. Neurorestorative properties of ibogaine: linking multi-receptor affinities to remyelination and metabolic restoration. Acta Neuropsychiatr. 2026;38:e26. https:\/\/doi.org\/10.1017\/neu.2026.10059.","journal-title":"Acta Neuropsychiatr"},{"issue":"2","key":"3814_CR16","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.3390\/molecules20022208","volume":"20","author":"X Koenig","year":"2015","unstructured":"Koenig X, Hilber K. The anti-addiction drug ibogaine and the heart: a delicate relation. Molecules. 2015;20(2):2208\u201328. https:\/\/doi.org\/10.3390\/molecules20022208.","journal-title":"Molecules"},{"issue":"10","key":"3814_CR17","doi-asserted-by":"publisher","first-page":"2475","DOI":"10.1021\/acschemneuro.8b00294","volume":"9","author":"MJ Wasko","year":"2018","unstructured":"Wasko MJ, Witt-Enderby PA, Surratt CK. DARK classics in chemical neuroscience: ibogaine. ACS Chem Neurosci. 2018;9(10):2475\u201383. https:\/\/doi.org\/10.1021\/acschemneuro.8b00294.","journal-title":"ACS Chem Neurosci"},{"key":"3814_CR18","unstructured":"Samorini G. Studies on the iboga cults V. Historical aspects. 2026. https:\/\/www.researchgate.net\/publication\/392496835_Studies_on_the_iboga_cults_V_Historical_aspects. Accessed  2026 Mar 30."},{"key":"3814_CR19","doi-asserted-by":"publisher","DOI":"10.1556\/2054.2026.00491","author":"G Ona","year":"2026","unstructured":"Ona G, Marie S. The long roots of ibogaine: a journey from plant to pharmaceutical. J Psychedelic Stud. 2026. https:\/\/doi.org\/10.1556\/2054.2026.00491.","journal-title":"J Psychedelic Stud"},{"key":"3814_CR20","doi-asserted-by":"publisher","unstructured":"Beyer J. Herbal psychoactive substances. In: Siegel JA, Saukko PJ, Houck MH, editors. Encyclopedia of forensic sciences (second edition). Oxford: Academic; 2013. p. 275\u2013279, ISBN 978-0-12-382166-9. https:\/\/doi.org\/10.1016\/B978-0-12-382165-2.00317-2.","DOI":"10.1016\/B978-0-12-382165-2.00317-2"},{"key":"3814_CR21","unstructured":"Overall J. Adversity as catalyst: a mixed-methods analysis of iboga-induced psychological transformation. J Conscious Explor Res. 2025;16(3):16(3):390\u2013421. Available from: https:\/\/jcer.com\/index.php\/jcj\/article\/view\/1177."},{"issue":"18","key":"3814_CR22","doi-asserted-by":"publisher","first-page":"18744","DOI":"10.1021\/acs.jmedchem.5c02510","volume":"68","author":"S Ali","year":"2025","unstructured":"Ali S, Tian X, Cunningham KA, Zhou J. Old dog, new tricks: ibogaine and its analogs as potential neurotherapeutics. J Med Chem. 2025;68(18):18744\u201351. https:\/\/doi.org\/10.1021\/acs.jmedchem.5c02510.","journal-title":"J Med Chem"},{"key":"3814_CR23","first-page":"850","volume":"133","author":"A Haller","year":"1901","unstructured":"Haller A, Heckel E. Sur l\u2019ibogine, principe actif d\u2019une plante du genre Tabernaemontana originaire du Congo. C R Acad Sci. 1901;133:850.","journal-title":"C R Acad Sci"},{"key":"3814_CR24","first-page":"748","volume":"133","author":"J Dybowski","year":"1901","unstructured":"Dybowski J, Landrin E. Sur l\u2019Iboga, sur ses propri\u00e9t\u00e9s excitantes, sa composition, et sur l\u2019alcalo\u00efde nouveau qu\u2019il renferme, l\u2019iboga\u00efne. CR Hebd Seances Acad Sci. 1901;133:748\u201350.","journal-title":"CR Hebd Seances Acad Sci"},{"key":"3814_CR25","unstructured":"Arag\u00f3n EO. LA SUPRESION DEL AGENTE CAUSAL EN LA PSICOSIS TOXICA EN PARTICULAR LAS ALCOHOLICAS. 1913."},{"key":"3814_CR26","unstructured":"Scribd. 2026. Pharmacodynamics and therapeutic applications of iboga and ibogaine. https:\/\/www.scribd.com\/document\/98103613\/Pharmacodynamics-and-Therapeutic-Applications-of-Iboga-and-Ibogaine. Accessed 2026 Apr 1."},{"key":"3814_CR27","unstructured":"Passie T. Psycholytic and psychedelic therapy research 1931 - 1995: a complete international bibliography. Hannover: Laurentius; 1997. p. 102 (Kleine bibliographische Reihe der Zeitschrift Laurentius Kleine bibliographische Reihe; no. 3)."},{"key":"3814_CR28","unstructured":"US-4499096-A - Patent Public Search | USPTO. 2026. https:\/\/ppubs.uspto.gov\/api\/patents\/html\/4499096?source=USPAT&requestToken=eyJzdWIiOiJhZTVhN2Q3Zi1jOGYwLTRhOTktOTQ5Ny02OTE1MmJjYTg4NGMiLCJ2ZXIiOiI3MGI1MmE1Mi1jYTI2LTQ4MDMtYjgyZC0zODEwZjdjZWI5MjgiLCJleHAiOjB9. Accessed 2026 Apr 2."},{"key":"3814_CR29","unstructured":"US-4587243-A - Patent Public Search | USPTO. 2026. https:\/\/ppubs.uspto.gov\/api\/patents\/html\/4587243?source=USPAT&requestToken=eyJzdWIiOiJhZTVhN2Q3Zi1jOGYwLTRhOTktOTQ5Ny02OTE1MmJjYTg4NGMiLCJ2ZXIiOiI3MGI1MmE1Mi1jYTI2LTQ4MDMtYjgyZC0zODEwZjdjZWI5MjgiLCJleHAiOjB9. Accessed 2026 Apr 2."},{"key":"3814_CR30","unstructured":"US-4857523-A - Patent Public Search | USPTO. 2026. https:\/\/ppubs.uspto.gov\/api\/patents\/html\/4857523?source=USPAT&requestToken=eyJzdWIiOiJhZTVhN2Q3Zi1jOGYwLTRhOTktOTQ5Ny02OTE1MmJjYTg4NGMiLCJ2ZXIiOiI3MGI1MmE1Mi1jYTI2LTQ4MDMtYjgyZC0zODEwZjdjZWI5MjgiLCJleHAiOjB9. Accessed 2026 Apr 2."},{"key":"3814_CR31","unstructured":"US-5026697-A - Patent Public Search | USPTO. 2026. https:\/\/ppubs.uspto.gov\/api\/patents\/html\/5026697?source=USPAT&requestToken=eyJzdWIiOiJhZTVhN2Q3Zi1jOGYwLTRhOTktOTQ5Ny02OTE1MmJjYTg4NGMiLCJ2ZXIiOiI3MGI1MmE1Mi1jYTI2LTQ4MDMtYjgyZC0zODEwZjdjZWI5MjgiLCJleHAiOjB9. Accessed 2026 Apr 2."},{"key":"3814_CR32","unstructured":"US-5152994-A - Patent Public Search | USPTO. 2026. https:\/\/ppubs.uspto.gov\/api\/patents\/html\/5152994?source=USPAT&requestToken=eyJzdWIiOiJhZTVhN2Q3Zi1jOGYwLTRhOTktOTQ5Ny02OTE1MmJjYTg4NGMiLCJ2ZXIiOiI3MGI1MmE1Mi1jYTI2LTQ4MDMtYjgyZC0zODEwZjdjZWI5MjgiLCJleHAiOjB9. Accessed 2026 Apr 2."},{"issue":"1","key":"3814_CR33","doi-asserted-by":"publisher","DOI":"10.1057\/s41285-025-00220-1","volume":"23","author":"J S\u00f6derberg","year":"2025","unstructured":"S\u00f6derberg J, Lundgren J. Risk management in a global market of alternative addiction care: a case study of the ibogaine medical subculture. Soc Theory Health. 2025;23(1):3. https:\/\/doi.org\/10.1057\/s41285-025-00220-1.","journal-title":"Soc Theory Health"},{"key":"3814_CR34","doi-asserted-by":"publisher","unstructured":"Wachtel B. Global legal status and medicalization models. Frameworks for Ibogaine and Psychedelics. 2025. https:\/\/doi.org\/10.13140\/RG.2.2.19596.17288.","DOI":"10.13140\/RG.2.2.19596.17288"},{"key":"3814_CR35","unstructured":"Simpson S. Texas to conduct its own ibogaine clinical trials. The Texas Tribune. 2026 Mar 31. https:\/\/www.texastribune.org\/2026\/03\/31\/texas-ibogaine-research-clinical-trials-psychedelics\/. Accessed 6 Apr 2026."},{"key":"3814_CR36","unstructured":"Governor Abbott Signs Ibogaine Treatment Research Law At Texas Capitol. 2026. https:\/\/gov.texas.gov\/news\/post\/governor-abbott-signs-ibogaine-treatment-research-law-at-texas-capitol. Accessed 2 Apr 2026."},{"issue":"1","key":"3814_CR37","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1021\/jacs.5c06325","volume":"148","author":"C Hwu","year":"2026","unstructured":"Hwu C, Havel V, Westergaard X, et al. Deciphering ibogaine\u2019s matrix pharmacology: multiple transporter modulation at serotonin synapses. J Am Chem Soc. 2026;148(1):175\u201393. https:\/\/doi.org\/10.1021\/jacs.5c06325.","journal-title":"J Am Chem Soc"},{"key":"3814_CR38","doi-asserted-by":"publisher","DOI":"10.1111\/bph.70088","author":"D Hoyer","year":"2025","unstructured":"Hoyer D. Psychedelics, entactogens and psychoplastogens for depression and related disorders. Br J Pharmacol. 2025. https:\/\/doi.org\/10.1111\/bph.70088.","journal-title":"Br J Pharmacol"},{"issue":"2","key":"3814_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurot.2024.e00322","volume":"21","author":"BR Barksdale","year":"2024","unstructured":"Barksdale BR, Doss MK, Fonzo GA, Nemeroff CB. The mechanistic divide in psychedelic neuroscience: an unbridgeable gap? Neurotherapeutics. 2024;21(2):e00322. https:\/\/doi.org\/10.1016\/j.neurot.2024.e00322.","journal-title":"Neurotherapeutics"},{"key":"3814_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.724606","volume":"12","author":"CMH de Vos","year":"2021","unstructured":"de Vos CMH, Mason NL, Kuypers KPC. Psychedelics and neuroplasticity: a systematic review unraveling the biological underpinnings of psychedelics. Front Psychiatry. 2021;12:724606. https:\/\/doi.org\/10.3389\/fpsyt.2021.724606.","journal-title":"Front Psychiatry"},{"key":"3814_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2024.1378841","volume":"18","author":"D Govender","year":"2024","unstructured":"Govender D, Moloko L, Papathanasopoulos M, Tumba N, Owen G, Calvey T. Ibogaine administration following repeated morphine administration upregulates myelination markers 2\u2032,3\u2032-cyclic nucleotide 3\u2032-phosphodiesterase (CNP) and myelin basic protein (MBP) mRNA and protein expression in the internal capsule of Sprague Dawley rats. Front Neurosci. 2024;18:1378841. https:\/\/doi.org\/10.3389\/fnins.2024.1378841.","journal-title":"Front Neurosci"},{"issue":"1","key":"3814_CR42","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/s41386-023-01717-x","volume":"49","author":"J Kim","year":"2024","unstructured":"Kim J, He MJ, Widmann AK, Lee FS. The role of neurotrophic factors in novel, rapid psychiatric treatments. Neuropsychopharmacology. 2024;49(1):227\u201345. https:\/\/doi.org\/10.1038\/s41386-023-01717-x.","journal-title":"Neuropsychopharmacology"},{"issue":"12","key":"3814_CR43","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1177\/02698811231200882","volume":"37","author":"G Ona","year":"2023","unstructured":"Ona G, Reverte I, Rossi GN, et al. Main targets of ibogaine and noribogaine associated with its putative anti-addictive effects: a mechanistic overview. J Psychopharmacol. 2023;37(12):1190\u2013200. https:\/\/doi.org\/10.1177\/02698811231200882.","journal-title":"J Psychopharmacol"},{"key":"3814_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1744383","volume":"16","author":"M Nicolas","year":"2025","unstructured":"Nicolas M. Ibogaine\u2019s potential role in supporting reward system recovery across diagnostic boundaries. Front Pharmacol. 2025;16:1744383. https:\/\/doi.org\/10.3389\/fphar.2025.1744383.","journal-title":"Front Pharmacol"},{"issue":"7966","key":"3814_CR45","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/s41586-023-06204-3","volume":"618","author":"R Nardou","year":"2023","unstructured":"Nardou R, Sawyer E, Song YJ, et al. Psychedelics reopen the social reward learning critical period. Nature. 2023;618(7966):790\u20138. https:\/\/doi.org\/10.1038\/s41586-023-06204-3.","journal-title":"Nature"},{"issue":"1","key":"3814_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s10020-024-01013-4","volume":"30","author":"RV Lima da Cruz","year":"2024","unstructured":"Lima da Cruz RV, Le\u00e3o RN, Moulin TC. Effects of psychedelics on neurogenesis and broader neuroplasticity: a systematic review. Mol Med. 2024;30(1):244. https:\/\/doi.org\/10.1186\/s10020-024-01013-4.","journal-title":"Mol Med"},{"key":"3814_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.glmedi.2025.100213","volume":"7","author":"RA Yockey","year":"2025","unstructured":"Yockey RA. Reconsidering ibogaine for the treatment of severe mental illness and substance use disorders. J Med Surg Public Health. 2025;7:100213. https:\/\/doi.org\/10.1016\/j.glmedi.2025.100213.","journal-title":"J Med Surg Public Health"},{"key":"3814_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2025.111533","volume":"142","author":"M Palhas","year":"2025","unstructured":"Palhas M, Corne R, Mongeau R. Changing your mind: neuroplastic mechanisms underlying the therapeutic effect of psychedelics in depression, PTSD, and addiction. Prog Neuropsychopharmacol Biol Psychiatry. 2025;142:111533. https:\/\/doi.org\/10.1016\/j.pnpbp.2025.111533.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"2","key":"3814_CR49","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2025-0171","volume":"15","author":"M Kabra","year":"2025","unstructured":"Kabra M, Srivastava T, Gautam R, et al. Effectiveness and safety of therapies for patients with opioid use disorder: a systematic review and network meta-analysis. J Comp Eff Res. 2025;15(2):e250171. https:\/\/doi.org\/10.57264\/cer-2025-0171.","journal-title":"J Comp Eff Res"},{"key":"3814_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.00529","volume":"9","author":"DC Mash","year":"2018","unstructured":"Mash DC, Duque L, Page B, Allen-Ferdinand K. Ibogaine detoxification transitions opioid and cocaine abusers between dependence and abstinence: clinical observations and treatment outcomes. Front Pharmacol. 2018;9:529. https:\/\/doi.org\/10.3389\/fphar.2018.00529.","journal-title":"Front Pharmacol"},{"issue":"1","key":"3814_CR51","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jep.2007.08.034","volume":"115","author":"KR Alper","year":"2008","unstructured":"Alper KR, Lotsof HS, Kaplan CD. The ibogaine medical subculture. J Ethnopharmacol. 2008;115(1):9\u201324. https:\/\/doi.org\/10.1016\/j.jep.2007.08.034.","journal-title":"J Ethnopharmacol"},{"key":"3814_CR52","doi-asserted-by":"publisher","first-page":"108717","DOI":"10.1016\/j.jsat.2021.108717","volume":"138","author":"P K\u00f6ck","year":"2022","unstructured":"K\u00f6ck P, Froelich K, Walter M, Lang U, D\u00fcrsteler KM. A systematic literature review of clinical trials and therapeutic applications of ibogaine. J Subst Abus Treat. 2022;138:108717. https:\/\/doi.org\/10.1016\/j.jsat.2021.108717.","journal-title":"J Subst Abus Treat"},{"key":"3814_CR53","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1111\/j.1749-6632.2000.tb05213.x","volume":"914","author":"DC Mash","year":"2000","unstructured":"Mash DC, Kovera CA, Pablo J, et al. Ibogaine: complex pharmacokinetics, concerns for safety, and preliminary efficacy measures. Ann N Y Acad Sci. 2000;914:394\u2013401. https:\/\/doi.org\/10.1111\/j.1749-6632.2000.tb05213.x.","journal-title":"Ann N Y Acad Sci"},{"key":"3814_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/s0099-9598(01)56005-8","volume":"56","author":"KR Alper","year":"2001","unstructured":"Alper KR. Ibogaine: a review. Alkaloids Chem Biol. 2001;56:1\u201338. https:\/\/doi.org\/10.1016\/s0099-9598(01)56005-8.","journal-title":"Alkaloids Chem Biol"},{"issue":"3","key":"3814_CR55","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1080\/02791072.2018.1447175","volume":"50","author":"BJ Malcolm","year":"2018","unstructured":"Malcolm BJ, Polanco M, Barsuglia JP. Changes in withdrawal and craving scores in participants undergoing opioid detoxification utilizing ibogaine. J Psychoact Drugs. 2018;50(3):256\u201365. https:\/\/doi.org\/10.1080\/02791072.2018.1447175.","journal-title":"J Psychoact Drugs"},{"issue":"2","key":"3814_CR56","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1556\/2054.01.2017.009","volume":"1","author":"AK Davis","year":"2017","unstructured":"Davis AK, Barsuglia JP, Windham-Herman AM, Lynch M, Polanco M. Subjective effectiveness of ibogaine treatment for problematic opioid consumption: short- and long-term outcomes and current psychological functioning. J Psychedelic Stud. 2017;1(2):65\u201373. https:\/\/doi.org\/10.1556\/2054.01.2017.009.","journal-title":"J Psychedelic Stud"},{"issue":"2","key":"3814_CR57","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/S0031-6997(25)06842-5","volume":"47","author":"P Popik","year":"1995","unstructured":"Popik P, Layer RT, Skolnick P. 100\u00a0years of ibogaine: neurochemical and pharmacological actions of a putative anti-addictive drug. Pharmacol Rev. 1995;47(2):235\u201353.","journal-title":"Pharmacol Rev"},{"issue":"2","key":"3814_CR58","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/S0006-8993(96)01414-X","volume":"749","author":"SD Glick","year":"1997","unstructured":"Glick SD, Maisonneuve IM, Pearl SM. Evidence for roles of kappa-opioid and NMDA receptors in the mechanism of action of ibogaine. Brain Res. 1997;749(2):340\u20133. https:\/\/doi.org\/10.1016\/S0006-8993(96)01414-X.","journal-title":"Brain Res"},{"issue":"1\u20132","key":"3814_CR59","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/0006-8993(93)90956-n","volume":"628","author":"SD Glick","year":"1993","unstructured":"Glick SD, Rossman K, Wang S, Dong N, Keller RW. Local effects of ibogaine on extracellular levels of dopamine and its metabolites in nucleus accumbens and striatum: interactions with D-amphetamine. Brain Res. 1993;628(1\u20132):201\u20138. https:\/\/doi.org\/10.1016\/0006-8993(93)90956-n.","journal-title":"Brain Res"},{"issue":"1","key":"3814_CR60","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1080\/00952990.2017.1310218","volume":"44","author":"GE Noller","year":"2018","unstructured":"Noller GE, Frampton CM, Yazar-Klosinski B. Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. Am J Drug Alcohol Abuse. 2018;44(1):37\u201346. https:\/\/doi.org\/10.1080\/00952990.2017.1310218.","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"3","key":"3814_CR61","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1177\/0960327107087802","volume":"27","author":"R Maciulaitis","year":"2008","unstructured":"Maciulaitis R, Kontrimaviciute V, Bressolle FMM, Briedis V. Ibogaine, an anti-addictive drug: pharmacology and time to go further in development. A narrative review. Hum Exp Toxicol. 2008;27(3):181\u201394. https:\/\/doi.org\/10.1177\/0960327107087802.","journal-title":"Hum Exp Toxicol"},{"issue":"10208","key":"3814_CR62","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1016\/S0140-6736(19)32229-9","volume":"394","author":"L Degenhardt","year":"2019","unstructured":"Degenhardt L, Grebely J, Stone J, et al. Global patterns of opioid use and dependence: harms to populations, interventions, and future action. Lancet. 2019;394(10208):1560\u201379. https:\/\/doi.org\/10.1016\/S0140-6736(19)32229-9.","journal-title":"Lancet"},{"issue":"4","key":"3814_CR63","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1056\/NEJMra1511480","volume":"374","author":"ND Volkow","year":"2016","unstructured":"Volkow ND, Koob GF, McLellan AT. Neurobiologic advances from the brain disease model of addiction. N Engl J Med. 2016;374(4):363\u201371. https:\/\/doi.org\/10.1056\/NEJMra1511480.","journal-title":"N Engl J Med"},{"issue":"5","key":"3814_CR64","doi-asserted-by":"publisher","first-page":"e826","DOI":"10.1038\/tp.2016.71","volume":"6","author":"M Belgers","year":"2016","unstructured":"Belgers M, Leenaars M, Homberg JR, Ritskes-Hoitinga M, Schellekens AFA, Hooijmans CR. Ibogaine and addiction in the animal model, a systematic review and meta-analysis. Transl Psychiatry. 2016;6(5):e826. https:\/\/doi.org\/10.1038\/tp.2016.71.","journal-title":"Transl Psychiatry"},{"issue":"2\u20133","key":"3814_CR65","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/0014-2999(93)90212-z","volume":"241","author":"SL Cappendijk","year":"1993","unstructured":"Cappendijk SL, Dzoljic MR. Inhibitory effects of ibogaine on cocaine self-administration in rats. Eur J Pharmacol. 1993;241(2\u20133):261\u20135. https:\/\/doi.org\/10.1016\/0014-2999(93)90212-z.","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"3814_CR66","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1007\/s002130050716","volume":"139","author":"SD Glick","year":"1998","unstructured":"Glick SD, Maisonneuve IM, Visker KE, Fritz KA, Bandarage UK, Kuehne ME. 18-Methoxycoronardine attenuates nicotine-induced dopamine release and nicotine preferences in rats. Psychopharmacology. 1998;139(3):274\u201380. https:\/\/doi.org\/10.1007\/s002130050716.","journal-title":"Psychopharmacology"},{"key":"3814_CR67","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/j.1749-6632.2000.tb06677.x","volume":"909","author":"SD Glick","year":"2000","unstructured":"Glick SD, Maisonneuve IM. Development of novel medications for drug addiction. the legacy of an African shrub. Ann N Y Acad Sci. 2000;909:88\u2013103. https:\/\/doi.org\/10.1111\/j.1749-6632.2000.tb06677.x.","journal-title":"Ann N Y Acad Sci"},{"issue":"1\u20132","key":"3814_CR68","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/0006-8993(94)90948-2","volume":"657","author":"SD Glick","year":"1994","unstructured":"Glick SD, Kuehne ME, Raucci J, et al. Effects of iboga alkaloids on morphine and cocaine self-administration in rats: relationship to tremorigenic effects and to effects on dopamine release in nucleus accumbens and striatum. Brain Res. 1994;657(1\u20132):14\u201322. https:\/\/doi.org\/10.1016\/0006-8993(94)90948-2.","journal-title":"Brain Res"},{"issue":"1","key":"3814_CR69","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2174\/15672050113109990001","volume":"6","author":"TK Brown","year":"2013","unstructured":"Brown TK. Ibogaine in the treatment of substance dependence. Curr Drug Abuse Rev. 2013;6(1):3\u201316. https:\/\/doi.org\/10.2174\/15672050113109990001.","journal-title":"Curr Drug Abuse Rev"},{"key":"3814_CR70","doi-asserted-by":"publisher","DOI":"10.1186\/s12868-026-01005-6","author":"A Acu\u00f1a","year":"2026","unstructured":"Acu\u00f1a A, Billeri F, Totaro V, et al. Ibogaine induces juvenile-like plasticity and modulates functional and structural regulators of plasticity in the adult mouse visual cortex. BMC Neurosci. 2026. https:\/\/doi.org\/10.1186\/s12868-026-01005-6.","journal-title":"BMC Neurosci"},{"issue":"4","key":"3814_CR71","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1111\/j.1369-1600.2010.00251.x","volume":"15","author":"S Carnicella","year":"2010","unstructured":"Carnicella S, He DY, Yowell QV, Glick SD, Ron D. Noribogaine, but not 18-MC, exhibits similar actions as ibogaine on GDNF expression and ethanol self-administration. Addict Biol. 2010;15(4):424\u201333. https:\/\/doi.org\/10.1111\/j.1369-1600.2010.00251.x.","journal-title":"Addict Biol"},{"issue":"6","key":"3814_CR72","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1001\/jama.2020.2012","volume":"325","author":"AK Patel","year":"2021","unstructured":"Patel AK, Balasanova AA. Treatment of alcohol use disorder. JAMA. 2021;325(6):596. https:\/\/doi.org\/10.1001\/jama.2020.2012.","journal-title":"JAMA"},{"issue":"10","key":"3814_CR73","doi-asserted-by":"publisher","first-page":"2617","DOI":"10.1111\/add.15357","volume":"116","author":"T Mekonen","year":"2021","unstructured":"Mekonen T, Chan GCK, Connor J, Hall W, Hides L, Leung J. Treatment rates for alcohol use disorders: a systematic review and meta-analysis. Addiction. 2021;116(10):2617\u201334. https:\/\/doi.org\/10.1111\/add.15357.","journal-title":"Addiction"},{"key":"3814_CR74","doi-asserted-by":"publisher","DOI":"10.47626\/2237-6089-2026-1437","author":"JM Rocha","year":"2026","unstructured":"Rocha JM, Maekawa RM, Reis JAS, et al. Feasibility, safety and preliminary effects of ibogaine in patients with moderate and severe alcohol use disorder: a pilot, open-label study. Trends Psychiatry Psychother. 2026. https:\/\/doi.org\/10.47626\/2237-6089-2026-1437.","journal-title":"Trends Psychiatry Psychother"},{"key":"3814_CR75","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.739012","volume":"12","author":"GM Henriques","year":"2021","unstructured":"Henriques GM, Anjos-Santos A, Rodrigues IRS, et al. Ibogaine blocks cue- and drug-induced reinstatement of conditioned place preference to ethanol in male mice. Front Pharmacol. 2021;12:739012. https:\/\/doi.org\/10.3389\/fphar.2021.739012.","journal-title":"Front Pharmacol"},{"issue":"23","key":"3814_CR76","doi-asserted-by":"publisher","first-page":"8114","DOI":"10.1073\/pnas.0711755105","volume":"105","author":"S Carnicella","year":"2008","unstructured":"Carnicella S, Kharazia V, Jeanblanc J, Janak PH, Ron D. GDNF is a fast-acting potent inhibitor of alcohol consumption and relapse. Proc Natl Acad Sci U S A. 2008;105(23):8114\u20139. https:\/\/doi.org\/10.1073\/pnas.0711755105.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"3814_CR77","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/s0091-3057(97)10003-x","volume":"58","author":"AH Rezvani","year":"1997","unstructured":"Rezvani AH, Overstreet DH, Yang Y, et al. Attenuation of alcohol consumption by a novel nontoxic ibogaine analogue (18-methoxycoronaridine) in alcohol-preferring rats. Pharmacol Biochem Behav. 1997;58(2):615\u20139. https:\/\/doi.org\/10.1016\/s0091-3057(97)10003-x.","journal-title":"Pharmacol Biochem Behav"},{"issue":"3","key":"3814_CR78","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/S0091-3057(03)00124-2","volume":"75","author":"AH Rezvani","year":"2003","unstructured":"Rezvani AH, Overstreet DH, Perfumi M, Massi M. Plant derivatives in the treatment of alcohol dependency. Pharmacol Biochem Behav. 2003;75(3):593\u2013606. https:\/\/doi.org\/10.1016\/S0091-3057(03)00124-2.","journal-title":"Pharmacol Biochem Behav"},{"key":"3814_CR79","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/bs.pbr.2018.08.002","volume":"242","author":"JP Barsuglia","year":"2018","unstructured":"Barsuglia JP, Polanco M, Palmer R, Malcolm BJ, Kelmendi B, Calvey T. A case report SPECT study and theoretical rationale for the sequential administration of ibogaine and 5-MeO-DMT in the treatment of alcohol use disorder. Prog Brain Res. 2018;242:121\u201358. https:\/\/doi.org\/10.1016\/bs.pbr.2018.08.002.","journal-title":"Prog Brain Res"},{"issue":"2","key":"3814_CR80","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1080\/08995605.2022.2156200","volume":"36","author":"SB Armstrong","year":"2024","unstructured":"Armstrong SB, Xin Y, Sepeda ND, Polanco M, Averill LA, Davis AK. Prospective associations of psychedelic treatment for co-occurring alcohol misuse and posttraumatic stress symptoms among United States Special Operations Forces Veterans. Mil Psychol. 2024;36(2):184\u201391. https:\/\/doi.org\/10.1080\/08995605.2022.2156200.","journal-title":"Mil Psychol"},{"issue":"7","key":"3814_CR81","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.jflm.2013.06.032","volume":"20","author":"SA Papadodima","year":"2013","unstructured":"Papadodima SA, Dona A, Evaggelakos CI, Goutas N, Athanaselis SA. Ibogaine related sudden death: a case report. J Forensic Leg Med. 2013;20(7):809\u201311. https:\/\/doi.org\/10.1016\/j.jflm.2013.06.032.","journal-title":"J Forensic Leg Med"},{"issue":"2","key":"3814_CR82","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1111\/j.1556-4029.2011.02008.x","volume":"57","author":"KR Alper","year":"2012","unstructured":"Alper KR, Staji\u0107 M, Gill JR. Fatalities temporally associated with the ingestion of ibogaine. J Forensic Sci. 2012;57(2):398\u2013412. https:\/\/doi.org\/10.1111\/j.1556-4029.2011.02008.x.","journal-title":"J Forensic Sci"},{"issue":"9","key":"3814_CR83","first-page":"422","volume":"70","author":"FP Paling","year":"2012","unstructured":"Paling FP, Andrews LM, Valk GD, Blom HJ. Life-threatening complications of ibogaine: three case reports. Neth J Med. 2012;70(9):422\u20134.","journal-title":"Neth J Med"},{"issue":"2","key":"3814_CR84","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/0306-4522(93)90500-f","volume":"55","author":"E O\u2019Hearn","year":"1993","unstructured":"O\u2019Hearn E, Molliver ME. Degeneration of Purkinje cells in parasagittal zones of the cerebellar vermis after treatment with ibogaine or harmaline. Neuroscience. 1993;55(2):303\u201310. https:\/\/doi.org\/10.1016\/0306-4522(93)90500-f.","journal-title":"Neuroscience"},{"issue":"1","key":"3814_CR85","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/s0006-8993(98)00207-8","volume":"797","author":"SJ Mah","year":"1998","unstructured":"Mah SJ, Tang Y, Liauw PE, Nagel JE, Schneider AS. Ibogaine acts at the nicotinic acetylcholine receptor to inhibit catecholamine release. Brain Res. 1998;797(1):173\u201380. https:\/\/doi.org\/10.1016\/s0006-8993(98)00207-8.","journal-title":"Brain Res"},{"issue":"1\u20133","key":"3814_CR86","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/s0014-2999(00)00122-9","volume":"393","author":"G Di Chiara","year":"2000","unstructured":"Di Chiara G. Role of dopamine in the behavioural actions of nicotine related to addiction. Eur J Pharmacol. 2000;393(1\u20133):295\u2013314. https:\/\/doi.org\/10.1016\/s0014-2999(00)00122-9.","journal-title":"Eur J Pharmacol"},{"issue":"1\u20132","key":"3814_CR87","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/s0014-2999(02)01284-0","volume":"438","author":"SD Glick","year":"2002","unstructured":"Glick SD, Maisonneuve IM, Kitchen BA, Fleck MW. Antagonism of alpha 3 beta 4 nicotinic receptors as a strategy to reduce opioid and stimulant self-administration. Eur J Pharmacol. 2002;438(1\u20132):99\u2013105. https:\/\/doi.org\/10.1016\/s0014-2999(02)01284-0.","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"3814_CR88","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1021\/acs.jmedchem.2c01562","volume":"66","author":"CJ Straub","year":"2023","unstructured":"Straub CJ, Rusali LE, Kremiller KM, Riley AP. What we have gained from ibogaine: \u03b13\u03b24 nicotinic acetylcholine receptor inhibitors as treatments for substance use disorders. J Med Chem. 2023;66(1):107\u201321. https:\/\/doi.org\/10.1021\/acs.jmedchem.2c01562.","journal-title":"J Med Chem"},{"issue":"3","key":"3814_CR89","doi-asserted-by":"publisher","first-page":"PL45","DOI":"10.1016\/0024-3205(95)00273-9","volume":"57","author":"DC Mash","year":"1995","unstructured":"Mash DC, Staley JK, Baumann MH, Rothman RB, Hearn WL. Identification of a primary metabolite of ibogaine that targets serotonin transporters and elevates serotonin. Life Sci. 1995;57(3):PL45-50. https:\/\/doi.org\/10.1016\/0024-3205(95)00273-9.","journal-title":"Life Sci"},{"issue":"2","key":"3814_CR90","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1002\/jcph.404","volume":"55","author":"P Glue","year":"2015","unstructured":"Glue P, Lockhart M, Lam F, Hung N, Hung CT, Friedhoff L. Ascending-dose study of noribogaine in healthy volunteers: pharmacokinetics, pharmacodynamics, safety, and tolerability. J Clin Pharmacol. 2015;55(2):189\u201394. https:\/\/doi.org\/10.1002\/jcph.404.","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"3814_CR91","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1177\/0269881115584461","volume":"29","author":"Q Chang","year":"2015","unstructured":"Chang Q, Hanania T, Mash DC, Maillet EL. Noribogaine reduces nicotine self-administration in rats. J Psychopharmacol. 2015;29(6):704\u201311. https:\/\/doi.org\/10.1177\/0269881115584461.","journal-title":"J Psychopharmacol"},{"issue":"9","key":"3814_CR92","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1097\/00001756-200006260-00041","volume":"11","author":"SD Glick","year":"2000","unstructured":"Glick SD, Maisonneuve IM, Dickinson HA. 18-MC reduces methamphetamine and nicotine self-administration in rats. NeuroReport. 2000;11(9):2013\u20135. https:\/\/doi.org\/10.1097\/00001756-200006260-00041.","journal-title":"NeuroReport"},{"issue":"3","key":"3814_CR93","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s002130050187","volume":"129","author":"IM Maisonneuve","year":"1997","unstructured":"Maisonneuve IM, Mann GL, Deibel CR, Glick SD. Ibogaine and the dopaminergic response to nicotine. Psychopharmacology. 1997;129(3):249\u201356. https:\/\/doi.org\/10.1007\/s002130050187.","journal-title":"Psychopharmacology"},{"issue":"8","key":"3814_CR94","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1523\/JNEUROSCI.0127-19.2020","volume":"41","author":"KS Elayouby","year":"2021","unstructured":"Elayouby KS, Ishikawa M, Dukes AJ, et al. \u03b13* nicotinic acetylcholine receptors in the habenula-interpeduncular nucleus circuit regulate nicotine intake. J Neurosci. 2021;41(8):1779\u201387. https:\/\/doi.org\/10.1523\/JNEUROSCI.0127-19.2020.","journal-title":"J Neurosci"},{"issue":"7083","key":"3814_CR95","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nature04710","volume":"440","author":"MC Sanguinetti","year":"2006","unstructured":"Sanguinetti MC, Tristani-Firouzi M. hERG potassium channels and cardiac arrhythmia. Nature. 2006;440(7083):463\u20139. https:\/\/doi.org\/10.1038\/nature04710.","journal-title":"Nature"},{"issue":"1","key":"3814_CR96","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1111\/add.15448","volume":"117","author":"T Knuijver","year":"2022","unstructured":"Knuijver T, Schellekens A, Belgers M, et al. Safety of ibogaine administration in detoxification of opioid-dependent individuals: a descriptive open-label observational study. Addiction. 2022;117(1):118\u201328. https:\/\/doi.org\/10.1111\/add.15448.","journal-title":"Addiction"},{"issue":"4","key":"3814_CR97","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/joa3.12061","volume":"34","author":"C Steinberg","year":"2018","unstructured":"Steinberg C, Deyell MW. Cardiac arrest after ibogaine intoxication. J Arrhythm. 2018;34(4):455\u20137. https:\/\/doi.org\/10.1002\/joa3.12061.","journal-title":"J Arrhythm"},{"issue":"1","key":"3814_CR98","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1093\/toxsci\/57.1.95","volume":"57","author":"Z Xu","year":"2000","unstructured":"Xu Z, Chang LW, Slikker W, Ali SF, Rountree RL, Scallet AC. A dose-response study of ibogaine-induced neuropathology in the rat cerebellum. Toxicol Sci. 2000;57(1):95\u2013101. https:\/\/doi.org\/10.1093\/toxsci\/57.1.95.","journal-title":"Toxicol Sci"},{"issue":"1\u20132","key":"3814_CR99","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/0006-8993(96)00739-1","volume":"737","author":"HH Molinari","year":"1996","unstructured":"Molinari HH, Maisonneuve IM, Glick SD. Ibogaine neurotoxicity: a re-evaluation. Brain Res. 1996;737(1\u20132):255\u201362. https:\/\/doi.org\/10.1016\/0006-8993(96)00739-1.","journal-title":"Brain Res"},{"issue":"6","key":"3814_CR100","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1002\/jcph.471","volume":"55","author":"P Glue","year":"2015","unstructured":"Glue P, Winter H, Garbe K, et al. Influence of CYP2D6 activity on the pharmacokinetics and pharmacodynamics of a single 20\u00a0mg dose of ibogaine in healthy volunteers. J Clin Pharmacol. 2015;55(6):680\u20137. https:\/\/doi.org\/10.1002\/jcph.471.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"3814_CR101","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/j.1749-6632.1998.tb08242.x","volume":"844","author":"DC Mash","year":"1998","unstructured":"Mash DC, Kovera CA, Buck BE, et al. Medication development of ibogaine as a pharmacotherapy for drug dependence. Ann N Y Acad Sci. 1998;844(1):274\u201392. https:\/\/doi.org\/10.1111\/j.1749-6632.1998.tb08242.x.","journal-title":"Ann N Y Acad Sci"},{"issue":"3","key":"3814_CR102","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1111\/ajad.12209","volume":"24","author":"CJ Marta","year":"2015","unstructured":"Marta CJ, Ryan WC, Kopelowicz A, Koek RJ. Mania following use of ibogaine: a case series. Am J Addict. 2015;24(3):203\u20135. https:\/\/doi.org\/10.1111\/ajad.12209.","journal-title":"Am J Addict"},{"issue":"5","key":"3814_CR103","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1177\/02698811241237873","volume":"38","author":"T Knuijver","year":"2024","unstructured":"Knuijver T, ter Heine R, Schellekens AFA, et al. The pharmacokinetics and pharmacodynamics of ibogaine in opioid use disorder patients. J Psychopharmacol. 2024;38(5):481\u20138. https:\/\/doi.org\/10.1177\/02698811241237873.","journal-title":"J Psychopharmacol"},{"issue":"12","key":"3814_CR104","doi-asserted-by":"publisher","first-page":"984","DOI":"10.3390\/medicina44120123","volume":"44","author":"A Kubiliene","year":"2008","unstructured":"Kubiliene A, Marksiene R, Kazlauskas S, Sadauskiene I, Razukas A, Ivanov L. Acute toxicity of ibogaine and noribogaine. Medicina (Kaunas). 2008;44(12):984\u20138.","journal-title":"Medicina (Kaunas)"},{"issue":"6","key":"3814_CR105","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1002\/cpdd.254","volume":"5","author":"P Glue","year":"2016","unstructured":"Glue P, Cape G, Tunnicliff D, et al. Ascending single-dose, double-blind, placebo-controlled safety study of noribogaine in opioid-dependent patients. Clin Pharmacol Drug Dev. 2016;5(6):460\u20138. https:\/\/doi.org\/10.1002\/cpdd.254.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"3814_CR106","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/j.1749-6632.2000.tb05211.x","volume":"914","author":"SD Glick","year":"2000","unstructured":"Glick SD, Maisonneuve IM, Szumlinski KK. 18-Methoxycoronaridine (18-MC) and ibogaine: comparison of antiaddictive efficacy, toxicity, and mechanisms of action. Ann N Y Acad Sci. 2000;914:369\u201386. https:\/\/doi.org\/10.1111\/j.1749-6632.2000.tb05211.x.","journal-title":"Ann N Y Acad Sci"},{"key":"3814_CR107","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/s0099-9598(01)56006-x","volume":"56","author":"SD Glick","year":"2001","unstructured":"Glick SD, Maisonneuve IM, Szumlinski KK. Mechanisms of action of ibogaine: relevance to putative therapeutic effects and development of a safer iboga alkaloid congener. Alkaloids Chem Biol. 2001;56:39\u201353. https:\/\/doi.org\/10.1016\/s0099-9598(01)56006-x.","journal-title":"Alkaloids Chem Biol"},{"issue":"13","key":"3814_CR108","doi-asserted-by":"publisher","first-page":"2716","DOI":"10.1021\/jm020562o","volume":"46","author":"ME Kuehne","year":"2003","unstructured":"Kuehne ME, He L, Jokiel PA, et al. Synthesis and biological evaluation of 18-methoxycoronaridine congeners. Potential antiaddiction agents. J Med Chem. 2003;46(13):2716\u201330. https:\/\/doi.org\/10.1021\/jm020562o.","journal-title":"J Med Chem"},{"issue":"7842","key":"3814_CR109","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41586-020-3008-z","volume":"589","author":"LP Cameron","year":"2021","unstructured":"Cameron LP, Tombari RJ, Lu J, et al. A non-hallucinogenic psychedelic analog with therapeutic potential. Nature. 2021;589(7842):474\u20139. https:\/\/doi.org\/10.1038\/s41586-020-3008-z.","journal-title":"Nature"},{"issue":"2","key":"3814_CR110","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1089\/psymed.2023.0009","volume":"1","author":"JA Heinsbroek","year":"2023","unstructured":"Heinsbroek JA, Giannotti G, Bonilla J, Olson DE, Peters J. Tabernanthalog reduces motivation for heroin and alcohol in a polydrug use model. Psychedelic Med (New Rochelle). 2023;1(2):111\u20139. https:\/\/doi.org\/10.1089\/psymed.2023.0009.","journal-title":"Psychedelic Med (New Rochelle)"},{"issue":"6","key":"3814_CR111","doi-asserted-by":"publisher","DOI":"10.3390\/ijms27062811","volume":"27","author":"I Anchesi","year":"2026","unstructured":"Anchesi I, Raffaele I, Astorino MF, Lui M, Calabr\u00f2 M, Cipriano GL. Beyond the genomic storm: evaluating tabernanthalog as a potential scaffold for silent neuroplasticity and broad-spectrum therapy. Int J Mol Sci. 2026;27(6):2811. https:\/\/doi.org\/10.3390\/ijms27062811.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"3814_CR112","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/j.1369-1600.2012.00447.x","volume":"19","author":"X Koenig","year":"2014","unstructured":"Koenig X, Kovar M, Boehm S, Sandtner W, Hilber K. Anti-addiction drug ibogaine inhibits hERG channels: a cardiac arrhythmia risk. Addict Biol. 2014;19(2):237\u20139. https:\/\/doi.org\/10.1111\/j.1369-1600.2012.00447.x.","journal-title":"Addict Biol"},{"issue":"11","key":"3814_CR113","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1038\/npp.2017.84","volume":"42","author":"RL Carhart-Harris","year":"2017","unstructured":"Carhart-Harris RL, Goodwin GM. The therapeutic potential of psychedelic drugs: past, present, and future. Neuropsychopharmacology. 2017;42(11):2105\u201313. https:\/\/doi.org\/10.1038\/npp.2017.84.","journal-title":"Neuropsychopharmacology"},{"issue":"12","key":"3814_CR114","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1177\/0269881116677852","volume":"30","author":"I Hartogsohn","year":"2016","unstructured":"Hartogsohn I. Set and setting, psychedelics and the placebo response: an extra-pharmacological perspective on psychopharmacology. J Psychopharmacol. 2016;30(12):1259\u201367. https:\/\/doi.org\/10.1177\/0269881116677852.","journal-title":"J Psychopharmacol"},{"issue":"3","key":"3814_CR115","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/nrn2590","volume":"10","author":"K Nader","year":"2009","unstructured":"Nader K, Hardt O. A single standard for memory: the case for reconsolidation. Nat Rev Neurosci. 2009;10(3):224\u201334. https:\/\/doi.org\/10.1038\/nrn2590.","journal-title":"Nat Rev Neurosci"},{"issue":"4","key":"3814_CR116","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.neubiorev.2012.01.002","volume":"36","author":"AL Milton","year":"2012","unstructured":"Milton AL, Everitt BJ. The persistence of maladaptive memory: addiction, drug memories and anti-relapse treatments. Neurosci Biobehav Rev. 2012;36(4):1119\u201339. https:\/\/doi.org\/10.1016\/j.neubiorev.2012.01.002.","journal-title":"Neurosci Biobehav Rev"},{"key":"3814_CR117","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.00733","volume":"9","author":"EE Schenberg","year":"2018","unstructured":"Schenberg EE. Psychedelic-assisted psychotherapy: a paradigm shift in psychiatric research and development. Front Pharmacol. 2018;9:733. https:\/\/doi.org\/10.3389\/fphar.2018.00733.","journal-title":"Front Pharmacol"},{"key":"3814_CR118","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/bs.apha.2020.05.004","volume":"89","author":"A Feder","year":"2020","unstructured":"Feder A, Rutter SB, Schiller D, Charney DS. The emergence of ketamine as a novel treatment for posttraumatic stress disorder. Adv Pharmacol. 2020;89:261\u201386. https:\/\/doi.org\/10.1016\/bs.apha.2020.05.004.","journal-title":"Adv Pharmacol"},{"issue":"2","key":"3814_CR119","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/s41591-023-02705-w","volume":"30","author":"KN Cherian","year":"2024","unstructured":"Cherian KN, Keynan JN, Anker L, et al. Magnesium\u2013ibogaine therapy in veterans with traumatic brain injuries. Nat Med. 2024;30(2):373\u201381. https:\/\/doi.org\/10.1038\/s41591-023-02705-w.","journal-title":"Nat Med"},{"issue":"4","key":"3814_CR120","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3109\/15563650.2016.1138226","volume":"54","author":"RPW Litjens","year":"2016","unstructured":"Litjens RPW, Brunt TM. How toxic is ibogaine? Clin Toxicol (Phila). 2016;54(4):297\u2013302. https:\/\/doi.org\/10.3109\/15563650.2016.1138226.","journal-title":"Clin Toxicol (Phila)"},{"issue":"7","key":"3814_CR121","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1007\/s00406-023-01590-1","volume":"273","author":"JM Rocha","year":"2023","unstructured":"Rocha JM, Reis JAS, Bouso JC, Hallak JEC, dos Santos RG. Identifying setting factors associated with improved ibogaine safety: a systematic review of clinical studies. Eur Arch Psychiatry Clin Neurosci. 2023;273(7):1527\u201342. https:\/\/doi.org\/10.1007\/s00406-023-01590-1.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"6","key":"3814_CR122","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1177\/0269881108093587","volume":"22","author":"M Johnson","year":"2008","unstructured":"Johnson M, Richards W, Griffiths R. Human hallucinogen research: guidelines for safety. J Psychopharmacol. 2008;22(6):603\u201320. https:\/\/doi.org\/10.1177\/0269881108093587.","journal-title":"J Psychopharmacol"},{"key":"3814_CR123","unstructured":"Fern\u00e1ndez JW, Fernandez RL. Bwiti: an ethnography of the religious imagination in Africa. Princeton Legacy Library edition. Princeton, NJ: Princeton University Press; 2019. p. 1. (Princeton Legacy Library; no. 5327)."},{"issue":"7","key":"3814_CR124","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","volume":"3","author":"RL Carhart-Harris","year":"2016","unstructured":"Carhart-Harris RL, Bolstridge M, Rucker J, et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry. 2016;3(7):619\u201327. https:\/\/doi.org\/10.1016\/S2215-0366(16)30065-7.","journal-title":"Lancet Psychiatry"},{"issue":"4","key":"3814_CR125","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/s0003-9993(95)80654-7","volume":"76","author":"JD Corrigan","year":"1995","unstructured":"Corrigan JD. Substance abuse as a mediating factor in outcome from traumatic brain injury. Arch Phys Med Rehabil. 1995;76(4):302\u20139. https:\/\/doi.org\/10.1016\/s0003-9993(95)80654-7.","journal-title":"Arch Phys Med Rehabil"},{"issue":"7","key":"3814_CR126","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1089\/neu.2008.0849","volume":"26","author":"JM Bjork","year":"2009","unstructured":"Bjork JM, Grant SJ. Does traumatic brain injury increase risk for substance abuse? J Neurotrauma. 2009;26(7):1077\u201382. https:\/\/doi.org\/10.1089\/neu.2008.0849.","journal-title":"J Neurotrauma"},{"key":"3814_CR127","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2022.887255","volume":"13","author":"M Cavarra","year":"2022","unstructured":"Cavarra M, Falzone A, Ramaekers JG, Kuypers KPC, Mento C. Psychedelic-assisted psychotherapy\u2014a systematic review of associated psychological interventions. Front Psychol. 2022;13:887255. https:\/\/doi.org\/10.3389\/fpsyg.2022.887255.","journal-title":"Front Psychol"},{"issue":"1 Suppl","key":"3814_CR128","doi-asserted-by":"publisher","first-page":"S79","DOI":"10.1016\/j.chest.2020.03.013","volume":"158","author":"EC Zabor","year":"2020","unstructured":"Zabor EC, Kaizer AM, Hobbs BP. Randomized controlled trials. Chest. 2020;158(1 Suppl):S79-87. https:\/\/doi.org\/10.1016\/j.chest.2020.03.013.","journal-title":"Chest"},{"issue":"8","key":"3814_CR129","doi-asserted-by":"publisher","first-page":"e781","DOI":"10.4088\/JCP.14f09362","volume":"75","author":"C Andrade","year":"2014","unstructured":"Andrade C. Cause versus association in observational studies in psychopharmacology. J Clin Psychiatry. 2014;75(8):e781-784. https:\/\/doi.org\/10.4088\/JCP.14f09362.","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"3814_CR130","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1093\/schbul\/sbac137","volume":"49","author":"DM Barch","year":"2022","unstructured":"Barch DM. The dangers of small samples and insufficient methodological detail. Schizophr Bull. 2022;49(1):5\u20136. https:\/\/doi.org\/10.1093\/schbul\/sbac137.","journal-title":"Schizophr Bull"},{"key":"3814_CR131","unstructured":"Shreffler J, Huecker MR. Type\u00a0I and type\u00a0II errors and statistical power. In: StatPearls. Treasure Island (FL): StatPearls; 2026. http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK557530\/.  Accessed 2026 Apr 23."},{"key":"3814_CR132","doi-asserted-by":"publisher","first-page":"69942","DOI":"10.12775\/QS.2026.54.69942","volume":"54","author":"M Majchrzyk","year":"2026","unstructured":"Majchrzyk M, Walendziak W, Ostaszewska M, et al. The efficacy and safety of ibogaine treatment for substance use disorders - a narrative review. Qual Sport. 2026;54:69942\u201369942. https:\/\/doi.org\/10.12775\/QS.2026.54.69942.","journal-title":"Qual Sport"},{"issue":"1","key":"3814_CR133","first-page":"003","volume":"29","author":"P Prior","year":"2014","unstructured":"Prior P, Prior S. Ibogaine effect on cocaine craving and use in dependent patients -a double- blind, placebo-controlled pilot study. J Addict Ther. 2014;29(1):003.","journal-title":"J Addict Ther"},{"issue":"2","key":"3814_CR134","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/1469-0691.12494","volume":"20","author":"WG Melsen","year":"2014","unstructured":"Melsen WG, Bootsma MCJ, Rovers MM, Bonten MJM. The effects of clinical and statistical heterogeneity on the predictive values of results from meta-analyses. Clin Microbiol Infect. 2014;20(2):123\u20139. https:\/\/doi.org\/10.1111\/1469-0691.12494.","journal-title":"Clin Microbiol Infect"},{"issue":"21","key":"3814_CR135","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare13212668","volume":"13","author":"EE Keighley","year":"2025","unstructured":"Keighley EE, Abo Hamza E, Bedewy DA, Nalla S, Moustafa AA. A systematic review and meta-analysis investigating the efficacy of various psychedelic drugs for the treatment of substance use disorder. Healthcare (Basel). 2025;13(21):2668. https:\/\/doi.org\/10.3390\/healthcare13212668.","journal-title":"Healthcare (Basel)"},{"issue":"1","key":"3814_CR136","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1080\/00952990.2017.1320802","volume":"44","author":"TK Brown","year":"2018","unstructured":"Brown TK, Alper K. Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes. Am J Drug Alcohol Abuse. 2018;44(1):24\u201336. https:\/\/doi.org\/10.1080\/00952990.2017.1320802.","journal-title":"Am J Drug Alcohol Abuse"},{"key":"3814_CR137","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00193","volume":"10","author":"S Marton","year":"2019","unstructured":"Marton S, Gonz\u00e1lez B, Rodr\u00edguez-Bottero S, et al. Ibogaine administration modifies GDNF and BDNF expression in brain regions involved in mesocorticolimbic and nigral dopaminergic circuits. Front Pharmacol. 2019;10:193. https:\/\/doi.org\/10.3389\/fphar.2019.00193.","journal-title":"Front Pharmacol"},{"issue":"11","key":"3814_CR138","doi-asserted-by":"publisher","DOI":"10.3390\/genes11111295","volume":"11","author":"C Taylor","year":"2020","unstructured":"Taylor C, Crosby I, Yip V, Maguire P, Pirmohamed M, Turner RM. A review of the important role of CYP2D6 in pharmacogenomics. Genes (Basel). 2020;11(11):1295. https:\/\/doi.org\/10.3390\/genes11111295.","journal-title":"Genes (Basel)"},{"key":"3814_CR139","doi-asserted-by":"crossref","unstructured":"Richer EJ. Ibogaine and the treatment of opiate addiction. In: Complementary and alternative therapies and the aging population. Academic; 2009. p. 393\u2013401. https:\/\/www.sciencedirect.com\/science\/chapter\/edited-volume\/abs\/pii\/B9780123742285000196.  Accessed 2026 May\u00a013.","DOI":"10.1016\/B978-0-12-374228-5.00019-6"},{"issue":"9","key":"3814_CR140","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1080\/17425255.2021.1944099","volume":"17","author":"M Luz","year":"2021","unstructured":"Luz M, Mash DC. Evaluating the toxicity and therapeutic potential of ibogaine in the treatment of chronic opioid abuse. Expert Opin Drug Metab Toxicol. 2021;17(9):1019\u201322. https:\/\/doi.org\/10.1080\/17425255.2021.1944099.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"3814_CR141","unstructured":"Chen S. Ibogaine treatment cost: complete pricing guide. https:\/\/ibogainetreatmentguide.com\/cost\/. Accessed 2026 Jun 12."},{"issue":"2","key":"3814_CR142","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1080\/08897077.2015.1010031","volume":"36","author":"H Jackson","year":"2015","unstructured":"Jackson H, Mandell K, Johnson K, Chatterjee D, Vanness DJ. Cost-effectiveness of injectable extended-release naltrexone compared with methadone maintenance and buprenorphine maintenance treatment for opioid dependence. Subst Abus. 2015;36(2):226\u201331. https:\/\/doi.org\/10.1080\/08897077.2015.1010031.","journal-title":"Subst Abus"},{"key":"3814_CR143","unstructured":"Center for Drug Evaluation and Research. Psychedelic drugs: considerations for clinical investigations. FDA; 2023. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/psychedelic-drugs-considerations-clinical-investigations.  Accessed 2026 Jun 12."},{"issue":"5","key":"3814_CR144","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","volume":"78","author":"AK Davis","year":"2021","unstructured":"Davis AK, Barrett FS, May DG, et al. Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiat. 2021;78(5):481\u20139. https:\/\/doi.org\/10.1001\/jamapsychiatry.2020.3285.","journal-title":"JAMA Psychiat"},{"key":"3814_CR145","unstructured":"The psychoactive drug ibogaine could save lives\u2014and everyone wants to cash in | National Geographic. https:\/\/www.nationalgeographic.com\/animals\/article\/ibogaine-pschedelic-drug-root-fair-trade-gabon. Accessed  2026 Jun 12."},{"key":"3814_CR146","unstructured":"Commissioner O of the. Right to Try. FDA. https:\/\/www.fda.gov\/patients\/learn-about-expanded-access-and-other-treatment-options\/right-try. Accessed  2026 Jun 12."},{"key":"3814_CR147","unstructured":"Cameron C. Scientific American. RFK, Jr., puts psychedelics on fast track to FDA review and approval. https:\/\/www.scientificamerican.com\/article\/rfk-jr-puts-psychedelics-on-fast-track-to-fda-review-and-approval\/. Accessed  2026 Jun 12."},{"key":"3814_CR148","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102711","volume":"74","author":"ME Hughes","year":"2024","unstructured":"Hughes ME, Garcia-Romeu A. Ethnoracial inclusion in clinical trials of psychedelics: a systematic review. EClinicalMedicine. 2024;74:102711. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102711.","journal-title":"EClinicalMedicine"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03814-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03814-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03814-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:12:52Z","timestamp":1792012372000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03814-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,14]]},"references-count":148,"alternative-id":["3814"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03814-x","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,14]]},"assertion":[{"value":"24 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors (Ahmed I. Anwar, Abdul-rahman A. Hegazi, M. Farris Sawaya, Joshua R. Nelson, Audrey E. Lashley, Jillian M. Gatti, Kristy M. Pham, Ibraheem A. Hachem, Molly E. McNulty, Destiny S. Lewis, Kevin S. Murnane, Alan D. Kaye) declare that they have no conflict of interest. Alan Kaye is an Editorial Board member of\n                      Advances in Therapy\n                      . Alan Kaye was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}